AIM Welcomes Global Fertility Innovator Dr. José A. Horcajadas to Advance the Future of Endometrial Intelligence

TORONTO, ON, CANADA, October 27, 2025 /EINPresswire.com/ — Synergyne ART Analytics Inc. (SART), exclusive developer of AIM, the AI-powered evolution of the Matris™ test, is proud to announce the addition of Dr. José A. Horcajadas, a globally recognized expert in reproductive biology and biotechnology innovation and visionary behind many of the world’s most widely adopted fertility diagnostics, to its scientific leadership team.

Dr. Horcajadas brings over 25 years of transformative leadership in translational research in assisted reproduction, specializing in endometrial receptivity, embryo assessment, and automation in IVF. His pioneering work includes the development of diagnostic tools such as ERA, ERMap, ERPeak, and MiFert&i—technologies that have fundamentally redefined modern fertility medicine worldwide.

As an active Advisory Board member, Dr. Horcajadas will catalyze the fusion of AIM’s cutting-edge AI imaging analytics with the deep molecular profiling for which he is famous. His mission is to ensure AIM continues to deliver unparalleled, clinically actionable insights for global fertility specialists. His role will unify research, product development, and clinical validation, leveraging his unparalleled expertise to cement AIM as the global gold standard in endometrial receptivity analysis.

“AIM represents a pivotal step forward in reproductive medicine,” said Dr. Horcajadas. “By fusing imaging analytics, artificial intelligence, and biological modeling, AIM moves beyond static concepts of endometrial receptivity toward a dynamic, individualized understanding. This approach delivers greater precision for clinicians and a more reliable, less invasive journey for patients.”

With the global fertility market rapidly evolving toward data-driven, non-invasive solutions, AIM is at the forefront—offering a scalable, intelligent platform that transforms complex biological signals into clear clinical guidance.

“This is a defining moment for AIM,” Dr. Horcajadas added. “The platform is moving from concept to clinical impact—bringing science, technology, and patient care into sharper alignment. I’m excited to help shape how AIM sets the new standard for endometrial assessment worldwide.”

“To have the visionary who created the ERA test join forces with AIM is a validation of our technology that speaks volumes,” said Steve Rowley, SART’s VP Business Development. “Dr. Horcajadas doesn’t just understand the science; he has an uncanny ability to ‘see around the corner’ of innovation and understands how fertility clinics operate globally. His insights were instrumental in our launch, and his official appointment was not just an obvious choice—it was essential for our mission.”

By combining proprietary artificial intelligence, imaging, and biological modeling, AIM offers a revolutionary new framework for fertility diagnostics—one that prioritizes accessibility, scalability, and real-world clinical utility. The addition of Dr. Horcajadas cements AIM’s position as the clear leader in this new frontier. It reinforces AIM’s commitment to advancing evidence-based innovation, allowing it to expand its impact across fertility clinics globally.

About AIM
AIM is the next generation of the Matris™ test—an AI-powered advancement in endometrial receptivity testing designed to enhance clinical efficiency and optimize fertility outcomes. AIM uses imaging and machine learning to deliver faster, more consistent, and personalized insights, empowering clinicians to make data-driven decisions that improve patient success.

For more information, visit aimfertility.com

Steve Rowley
Synergyne ART Analytics Inc.
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.